Study finds planetary waves linked to wild summer weather have tripled since 1950
WASHINGTON — Climate change has tripled the frequency of atmospheric wave events linked to extreme summer weather in the last 75 years and that may explain why long-range computer forecasts keep underestimating the surge in killer heat waves, droughts and floods, a new study says.
In the 1950s, Earth averaged about one extreme weather-inducing planetary wave event a summer, but now it is getting about three per summer, according to a study in Monday's Proceedings of the National Academy of Sciences. Planetary waves are connected to 2021's deadly and unprecedented Pacific Northwest heat wave , the 2010 Russian heatwave and Pakistan flooding and the 2003 killer European heatwave , the study said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH
LungFit PH II's smaller, lightweight, transport-ready design is expected to open the entirety of the NO market Final design based upon substantial feedback from respiratory therapists across the countryGARDEN CITY, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ('Beyond Air' or the 'Company'), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the submission of a premarket approval (PMA) supplement application to the U.S. Food and Drug Administration (FDA) for LungFit PH II, the next-generation therapeutic nitric oxide generator. Beyond Air has developed its LungFit PH II system to be smaller, lighter and fully transport-ready — while delivering all the breakthrough features of the currently FDA-approved version from the Company's therapeutic platform of nitric oxide generators targeting pulmonary disease. The new system uses the same Smart Filter and accessories as the first-generation device, ensuring continuity, streamlined logistics, and minimal disruption for existing customers. The LungFit PH platform uses the Company's patented Ionizer™ technology to generate unlimited on-demand nitric oxide from ambient air, which is then able to be delivered directly to a ventilator circuit, regardless of dose or flow. The LungFit PH system uses the equivalent power of a 60-watt lightbulb to ionize the nitrogen and oxygen molecules, forming nitric oxide with low levels of nitrogen dioxide (NO2) created as a byproduct. The gas then passes through a Smart Filter, which removes the toxic NO2 from the internal circuit. For the treatment of PPHN, the novel LungFit PH system is designed to deliver NO doses consistent with the current standard of care for delivery of 20 ppm NO, with a range of 0.5 ppm – 80 ppm (low concentration NO), for ventilated patients. Each Smart Filter provides 12 hours of therapy regardless of ventilator demands and can be replaced in seconds for uninterrupted treatment. 'We are pleased to announce that development of our transport-ready LungFit PH II has resulted in a NO system which we believe is far superior to legacy systems currently available in the market. While our first-generation system already delivers key advantages to hospitals, this next-generation device raises the bar with a reduced weight and footprint, simplified operation, longer service interval, and full compatibility with both air and ground transport. It also includes an automated backup system that retains most primary system capabilities,' said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. 'Once approved, we are confident that the introduction of LungFit PH II will play a pivotal role in accelerating our market expansion and advancing our position as a global leader in hospital-based NO delivery.' NO gas is a vasodilator approved in dozens of countries to improve oxygenation and reduce the need for extracorporeal membrane oxygenation (ECMO) in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilator support and other appropriate agents. Low concentration inhaled NO therapy has been the standard-of-care for PPHN for over 20 years in the United States. PPHN is a lethal condition and secondary to failure of normal circulatory transition at birth. It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due to decreased pulmonary blood flow and right-to-left shunting of blood. Its incidence has been reported as 1.9 per 1,000 live births (0.4-6.8/1,000 live births) with a mortality rate ranging between 4-33%. This syndrome complicates the course of about 10% of infants with respiratory failure and remains a source of considerable morbidity and mortality. In the European Union and many other countries outside the United States, NO is also approved for the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function. About LungFit *Beyond Air's LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders, providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety by eliminating NO2 purging steps, and offering other operational benefits. LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting. *Beyond Air's LungFit PH is approved for commercial use in the United States, European Union, Australia, Thailand and New Zealand. Beyond Air's other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home. About PPHNPersistent pulmonary hypertension of the newborn (PPHN) is a lethal condition and secondary to failure of normal circulatory transition at birth. It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due to decreased pulmonary blood flow and right-to-left shunting of blood. Its incidence has been reported as 1.9 per 1,000 live births (0.4–6.8/1000 live births) with mortality rate ranging between 4–33%. This syndrome complicates the course of about 10% of infants with respiratory failure and remains a source of considerable morbidity and mortality. NO gas is a vasodilator, is approved in dozens of countries to improve oxygenation and reduces the need for extracorporeal membrane oxygenation (ECMO) in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilator support and other appropriate agents. About Beyond Air®, Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM). The Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit Forward Looking StatementsThis press release contains 'forward-looking statements' concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words 'appears,' 'expects,' 'plans,' 'anticipates,' 'believes' 'expects,' 'intends,' 'looks,' 'projects,' 'goal,' 'assumes,' 'targets' and similar expressions and/or the use of future tense or conditional constructions (such as 'will,' 'may,' 'could,' 'should' and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the 'Risk Factors' section of Beyond Air's most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air's website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law. CONTACTS:Investor Relations contactsCorey Davis, Advisors, LLCCdavis@ 915-2577 A photo accompanying this announcement is available at
Digital Trends
an hour ago
- Digital Trends
Amazon's Kuiper satellite launch called off 30 minutes before liftoff
Amazon is keen to get its second batch of internet satellites into orbit, but it won't be happening just yet. The launch of 27 Project Kuiper satellites was set to take place early Monday afternoon ET at Cape Canaveral in Florida, but just 30 minutes from liftoff, rocket operator United Launch Alliance (ULA) said it was standing down for the day 'due to an engineering observation of an elevated purge temperature within the booster engine' on its Atlas V vehicle. In simple terms, this means part of the booster became too hot and needs to be investigated. Recommended Videos ULA said it will release a new launch date just as soon as one is decided. The rocket had been due to launch last Friday, but poor weather conditions prompted mission planners to shift the date to Monday. Similar to SpaceX's established Starlink service, Amazon's Project Kuiper aims to provide fast, affordable broadband internet to customers globally. It's particularly keen to serve locations where fiber, cable, or cellular infrastructure is unavailable or unreliable, such as rural and mountainous areas, while the service could also play an important role in disaster zones — something that Starlink has done a number of times in recent years to support emergency and relief efforts. The company plans to deploy a constellation of 3,236 satellites in low Earth orbit, which will be completed by 2029 at the latest. Before then, Amazon is aiming to launch a high-speed broadband service by the end of this year with around 1,000 satellites, though building the constellation over time will improve network performance and reliability for what the company expects to be a growing customer base. To deploy its internet satellites, Amazon has secured more than 90 rocket launches with a slew of spaceflight firms that include not only ULA but also ArianeGroup, Blue Origin, and even SpaceX, spending more than $10 billion in launch contracts. Customers signing up to the Project Kuiper service will be able to choose from three types of user terminals: a compact 7-inch square model for portability (up to 100 Mbps), a standard 11-inch model for households (up to 400 Mbps), and a larger model for enterprises (up to 1 Gbps). Amazon expects to sell its standard customer terminal for around $400 per unit, which would make it about $50 more expensive than Starlink's terminal for residential customers. Interested in watching the launch? Digital Trends has everything you need to know.
Yahoo
an hour ago
- Yahoo
There may be a ‘third state' between life and death
If you purchase an independently reviewed product or service through a link on our website, BGR may receive an affiliate commission. As humans, we typically look at life and death as two sides of the same coin. However, some researchers believe there could be a 'third state' between the two. One piece of evidence for this additional state is the way we continue to use organs, tissues, and cells beyond when the organism they're attached to dies. Somehow, they continue living. In a post on The Conversation, researchers behind a new paper break down exactly how they think these biobots exist, and how they were able to take cells and turn them into multicellular organisms with new functions after their death. Despite how it sounds, these aren't zombie cells. Instead, they appear to be new organisms with an entirely different life to live. Today's Top Deals Best deals: Tech, laptops, TVs, and more sales Best Ring Video Doorbell deals Memorial Day security camera deals: Reolink's unbeatable sale has prices from $29.98 But how exactly does this prove that there is a third state beyond life and death? Well, typically death is viewed as the irreversible end of an organism. At that point, there's no more functioning for the organism in question. But that isn't the case here. Instead, the researchers proved that certain cells could live on and be changed into something completely different. This third state then, challenges everything scientists understand about cell behavior. Because they can turn the already existing cells into new organisms with different purposes, they have started calling them living robots. These organisms could have multiple uses in medical and scientific fields, though researchers are still working to understand exactly how this happens. There are plenty of examples of organisms transforming or transitioning into something different. However, it is very rare that an organism can change in ways that are not already predetermined. That's the real difference between this third state of being and the transformations seen in some creatures like butterflies or tadpoles. Depending on the origin of the living robot, the functions they unlock upon their transformation can vary. For instance, the researchers found that solitary human lung cells can actually self-assemble into new multicellular organisms called anthrobots. These living robots then behave in new ways. They can both navigate the area around them as well as repair themselves and injured neuron cells that are placed nearby. But there are conditions for how these cells continue living after their host organism's death. The researchers write that several factors, from how long it has been since the organism died to how active metabolic activity is at the time of death, can greatly affect the birth of this third state of being. Additionally, factors such as health, sex, and age can shape the postmortem landscape, too. Understanding exactly how this third state comes into play in the wild will require deeper research. For now, though, this new study is at least evidence that there is something out there beyond life and death, at least for certain cells. What that means in the grand scheme of things remains to be seen. More Top Deals Amazon gift card deals, offers & coupons 2025: Get $2,000+ free See the
